Live Breaking News & Updates on Citius pharma

Stay informed with the latest breaking news from Citius pharma on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Citius pharma and stay connected to the pulse of your community

EY names 26 finalists for 2024 NJ Entrepreneur of the Year award

EY names 26 finalists for 2024 NJ Entrepreneur of the Year award
njbiz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from njbiz.com Daily Mail and Mail on Sunday newspapers.

Jersey-city , New-jersey , United-states , Roseland , Manalapan , Asbury-park , Paramus , Long-valley , Cranbury , Newark , Whippany , Hoboken

Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states , Phoenix , Arizona , California , Chicago , Illinois , University-of-minnesota , Minnesota , Orange-county , Los-angeles , Ilanit-allen , Myron-czuczman

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing...

California , United-states , University-of-minnesota , Minnesota , Phoenix , Arizona , Chicago , Illinois , Orange-county , Matthew-mei , Citius-pharma , Myron-czuczman

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New-york , United-states , Citius-pharma , Ilanit-allen , Leonard-mazur , Company-nasdaq , Sofitel , Citius-pharmaceuticals-inc , Prnewswire-citius-pharmaceuticals-inc , Citius-pharmaceuticals , Biologics-license-application , Citius-oncology

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration

CRANFORD, N.J., Feb. 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. , a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical...

Ilanit-allen , Citius-pharma , Citius-pharmaceuticals-inc , Company-nasdaq , Prnewswire-citius-pharmaceuticals-inc , Exchange-commission , Citius-pharmaceuticals , Biologics-license-application , Citius-oncology , Markets ,

Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences

CRANFORD, N.J., Feb. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. , a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical...

New-york , United-states , Marriott-marquis , Citius-pharma , Ilanit-allen , Leonard-mazur , Prnewswire-citius-pharmaceuticals-inc , Citius-pharmaceuticals-inc , Company-nasdaq , Investor-conference , Sidoti-small-cap-virtual-conference , Investor-conference-details

Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...

Japan , Greg-salsburg , Citius-pharma , Ilanit-allen , Company-biologics-license-application , Exchange-commission , Citius-pharmaceuticals-inc , Securities-exchange , Company-nasdaq , Prnewswire-citius-pharmaceuticals-inc , Drug-administration , Investor-relations-for-citius-pharmaceuticals

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

Resubmitted LYMPHIR™ Biologics License Application; awaiting PDUFA date
Completed enrollment in the Mino-Lok® Pivotal Phase 3 trial
CRANFORD, N.J., Feb. 14, 2024 /PRNewswire/ -- Citius...

New-jersey , United-states , Greg-salsburg , Ilanit-allen , Robert-smith , Citius-pharma , Leonard-mazur , Drug-administration , Citius-pharmaceuticals-inc , Securities-exchange , Citius-oncology-inc , Company-nasdaq

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...

New-jersey , United-states , Leonard-mazur , Greg-salsburg , Ilanit-allen , Robert-smith , Citius-pharma , Citius-pharmaceuticals-inc , Development-rd-expenses , Securities-exchange , Prnewswire-citius-pharmaceuticals-inc , Drug-administration

Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors

Independent Director nominee expected to be elected at Annual Shareholders' Meeting in March 2024
CRANFORD, N.J., Jan. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. , a late-stage...

Jersey , Wisconsin , United-states , New-york , Pennsylvania , Virginia , Rochester , Charlottesville , University-of-rochester , Ilanit-allen , Leonard-mazur , Robertj-smith